zithromax has been researched along with Fetal-Death* in 2 studies
2 trial(s) available for zithromax and Fetal-Death
Article | Year |
---|---|
Child Health Outcomes After Presumptive Infection Treatment in Pregnant Women: A Randomized Trial.
We showed earlier that presumptive infection treatment in pregnancy reduced the prevalence of neonatal stunting in a rural low-income setting. In this article, we assess how these gains were sustained and reflected in childhood growth, development, and mortality.. We enrolled 1320 pregnant Malawian women in a randomized trial and treated them for malaria and other infections with either 2 doses of sulfadoxine-pyrimethamine (SP) (control), monthly SP, or monthly sulfadoxine-pyrimethamine and 2 doses of azithromycin (AZI-SP). Child height or length and mortality were recorded at 1, 6, 12, 24, 36, 48, and 60 months and development at 60 months by using Griffith's Mental Development Scales.. Throughout follow-up, the mean child length was 0.4 to 0.7 cm higher (. Provision of AZI-SP rather than 2 doses of SP during pregnancy reduced the incidence of stunting in childhood. AZI-SP during pregnancy also had a positive effect on child development and may have reduced postneonatal mortality. Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Child Development; Child Health; Child Mortality; Child, Preschool; Drug Combinations; Female; Fetal Death; Follow-Up Studies; Growth Disorders; Humans; Incidence; Infant; Malaria; Malawi; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Complications, Parasitic; Prevalence; Pyrimethamine; Rural Population; Sulfadoxine | 2018 |
Role of cervical cerclage and prolonged antibiotic therapy with azithromycin in patients with previous perinatal loss amnionitis.
In the group of 35 patients with cerclage, intermediate fetal mortality was reduced from 37.1% to 0 (p < 0.001); late fetal mortality rate from 8.5% to 2.8% (p = 0.606); prematurity from 65.7% to 5.7% (p < 0.001); newborn underweight from 11.4% to 5.7% (p = 0.671); newborns with very low weight from 34.2% to 0 (p < 0.001) and the abortion rate from 8.5% to 0 ( p < 0.001). In the group of 19 patients without buckling, intermediate fetal mortality was reduced from 26.3% to 10.5% (p = 402); late fetal mortality from 63.1% to 0 (p < 0.001); prematurity 78.9% to 31.5% (p < 0.009); the newborn of low weight from 31.5% to 10.5% (p = 0.234); newborns with very low weight from 68.4% to 15.7% (p < 0.003) and the abortion rate from 36.8 to 0 (p < 0.001). In conclusion, we believe the results of this study demonstrate the effectiveness of therapeutic and prophylactic cervical cerclage associated with prolonged antibiotic therapy. Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cerclage, Cervical; Chorioamnionitis; Drug Administration Schedule; Female; Fetal Death; Humans; Pregnancy; Premature Birth; Prospective Studies; Risk Factors; Treatment Outcome | 2017 |